Showing results (511-520 of 2,338) with videos related to

Sort By:
Pageof 234
Clinical Lung Cancer|November 21, 2024
Augmenting Prognostication: Utilizing Activity Trackers to Enhance Survival Prediction in Metastatic Non-Small Cell Lung CancerYeonjung Jo, Sonam Puri, Benjamin Haaland, et al.
Clinical Lung Cancer|August 13, 2024
RBM10 Mutation as a Potential Negative Prognostic/Predictive Biomarker to Therapy in Non-Small-Cell Lung CancerAmanda Reyes, Michelle Afkhami, Erminia Massarelli, et al.
Clinical Lung Cancer|August 9, 2024
Characteristics of Lung Cancer Patients With Asymptomatic or Undiagnosed SARS-CoV-2 InfectionsMedha Somisetty, Philip C Mack, Chih-Yuan Hsu, et al.
Clinical Lung Cancer|July 11, 2024
The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain MetastasesXiancheng Wu, Laura P Stabile, Timothy F Burns
Clinical Lung Cancer|August 3, 2024
Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung CancerMartin Reck, Tuli De, Luis Paz-Ares, et al.
Clinical Lung Cancer|August 2, 2024
Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective StudyYosuke Kakiuchi, Koichi Saruwatari, Kenta Murotani, et al.
Clinical Lung Cancer|August 2, 2024
Evaluating Safety and Clinical Activity of Front-line Treatment with Cadonilimab plus Chemotherapy in Advanced/Metastatic Nonsmall Cell Lung Cancer Harboring STK11 Genetic Aberration: A Protocol of Phase II StudyHuixin Jiang, Ni Sun, Ru Li, et al.
Clinical Lung Cancer|October 25, 2023
Smoking, Diabetes Mellitus, and Previous Cardiovascular Disease as Predictors of Anticancer Treatment-Induced Cardiotoxicity in Non-Small-Cell Lung Cancer: A Real-World StudyHasan Kobat, Islam Elkonaissi, Emma Foreman, et al.
Clinical Lung Cancer|November 1, 2023
TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical ResectionRoss Andrew Soo, Filippo de Marinis, Ji-Youn Han, et al.
Clinical Lung Cancer|September 6, 2023
Patient-Provider Discussion About Lung Cancer Screening by Race and Ethnicity: Implications for Equitable Uptake of Lung Cancer ScreeningYoung-Rock Hong, Meghann Wheeler, Ruixuan Wang, et al.
Pageof 234